ALSO NOTED: GSK suing Abbott over HIV-drug price; Harvard genius joins MIT-Novartis effort;

> GlaxoSmithKline is joining a lawsuit against Abbott Laboratories over the jacked-up price of Norvir, and anti-HIV drug. Report

> A top Harvard chemist will join the MIT-Novartis Center for Continuous Manufacturing, a joint effort of the university and the Big Pharma company to develop new ways of making drugs. Report

> The FDA approved new labeling for the Bristol-Myers Squibb leukemia drug Sprycel; patients can now start on a lower dose of the drug, to help avert side effects. Report

> Indian pharma Wockhardt is considering a spin-off of its R&D operations, in the wake of similar moves by competitors. Report

> The FDA: Caught between a rock and a hard place. Report

And Finally... Athletes given placebo on competition day get a performance boost. Report

Suggested Articles

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.

After a jury ordered Gilead's Kite Pharma to pay $752 million for CAR-T patent infringement, BMS is asking for punitive damages in that amount, too.